Synonyms: BION-1301 | BION1301 | clone 14_1G.15
Compound class:
Antibody
Comment: Zigakibart is an anti-TNFSF13 (APRIL) monoclonal antibody that has been designed for anti-inflammatory potential. Amino acid sequences for zigakibart's heavy and light chains (obtained from INN documentation) match the sequences for clone 14_1G.15 as claimed in patent US9969808B2 (Aduro Biotech) [1]. Aduro Biotech merged into Chinook Therapeutics in mid-2020, with this new entity holding the humanized IgG4 anti-APRIL mAb BION-1301 in its development portfolio. We predict that zigakibart is the INN for BION-1301. BION-1301 is described as blocking APRIL binding to both the BCMA and TACI receptors, to down-modulate B cell functions.
|
No information available. |
Summary of Clinical Use |
Evaluation of BION-1301 for efficacy in patients with IgA nephropathy is ongoing. |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT03340883 | Safety and Tolerability of BION-1301 in Adults With Relapsed or Refractory Multiple Myeloma (MM) | Phase 1/Phase 2 Interventional | Chinook Therapeutics, Inc. | This study was terminated as no indicators of beneficial effect were detected following completion of the Phase 1 dose-escalation. | |
NCT03945318 | Safety and Tolerability of BION-1301 in Healthy Volunteers and Adults With IgA Nephropathy (IgAN) | Phase 1/Phase 2 Interventional | Chinook Therapeutics, Inc. |